Additionally, the tumor immunity response to both treatments was quite different, as implied from the elevated expression levels of immune cell markers, including CD8, CD4, CD3 and CD45, as well as antitumor effector cytokines including IFN-γ and TNF-α. This evidence concerns the gene PTPRC and neoplasm.